Cáncer de mama: análisis desde perspectivas transdisciplinar, psicosocial y de género en Chile y Cataluña / Breast cancer: analysis from transdisciplinary, psychosocial and gender perspectives in Chile and Catalonia

FUNDAMENTOS: El cáncer de mama es la primera causa de muerte por cáncer en la mujer a nivel mundial. Nuestro objetivo fue comparar las políticas públicas sanitarias de cáncer de mama en Chile y Cataluña, bajo las perspectivas transdisciplinar, psicosocial y de género. MATERIAL Y MÉTODOS: Estudio cualitativo descriptivo que utilizó como método y técnica el análisis comparativo entre políticas públicas sobre cáncer de mama en Chile y Cataluña desde el año 2005 al 2016. RESULTADOS: Ninguna región considera la perspectiva transdisciplinar, y ambos sitios sólo trabajan desde un abordaje multidisciplinar. Por su parte, la perspectiva psicosocial fue descrita como relevante en el ciclo de la enfermedad; no obstante, se reduce a lo disciplinar en ambos contextos. Con respecto a la perspectiva de género, Chile señala su incorporación en las estrategias, pero no es consistente, mientras Cataluña menciona pequeños elementos sin explicitar el enfoque. Entre las categorías emergentes, se incluyen la perspectiva política/ epidemiológica, con ambos espacios prioritizando la elaboración y ejecución de las políticas públicas para la patología, y la perspectiva del empoderamiento de las usuarias, la cual ambas regiones identifican como eje fundamental en la toma de decisiones médicas. CONCLUSIONES: Existe un estado incipiente al abordar las perspectivas analizadas, sin embargo, no condicen con las demandas sociales ni el avance epistemológico sanitario. En lo comparativo, existen mayores similitudes que diferencias, ambos manifiestan una precaria articulación de los planteamientos analizados. Por ahora, es importante comenzar transformando la comprensión sobre el cáncer de mama, tarea pendiente será su materialización en protocolos y guías sanitarias.

BACKGROUND: Breast cancer is the leading cause of cancer death in women worldwide. Our objective was to compare the public health policies of breast cancer in Chile and Catalonia, under transdisciplinary, psychosocial and gender perspectives. MATERIAL AND METHODS: Qualitative descriptive study, which used the method of comparative analysis to compare public policies on breast cancer in Chile and Catalonia between 2005 and 2016. RESULTS: The transdisciplinary perspective was not considered, with both regions only taking a multidisciplinary approach. For its part, the psychosocial perspective was described as relevant in the disease cycle, but in practice both sites showed limited application of this perspective. With respect to the gender perspective, Chile has incorporated it into strategies, though not consistently manner, while Catalonia mentions small elements, without being explicit about the approach. The identified emergent categories include a political/epidemiological perspective, with both locations prioritizing the development and execution of public policies to address the pathology, as well as a perspective of user empowerment, which both Chile and Catalonia identify as a fundamental aspect of medical decision making. CONCLUSIONS: The analyzed perspectives are in early stages of development; however, they are not yet in line with social demands nor current health epistemology. In terms of the comparison, there are greater similarities than differences between the two sites, and both are just starting to articulate the analyzed approaches. For now, it is important that both sites start transforming their understanding of breast cancer, and a pending task will be to materialize that new approach into health protocols and guides.

Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study.

BACKGROUND: Premorbid metabolic syndrome (pre-MetS) is a cluster of cardiometabolic risk factors characterised by central obesity, elevated fasting glucose, atherogenic dyslipidaemia and hypertension without established cardiovascular disease or diabetes. Community pharmacies are in an excellent position to develop screening programmes because of their direct contact with the population.The main aim of the study was to determine the prevalence of pre-MetS in people who visited community pharmacies for measurement of any of its five risk factors to detect the presence of other risk factors. The secondary aims were to study the presence of other cardiovascular risk factors and determine patients' cardiovascular risk. METHODS: Cross-sectional, descriptive, multicentre study. Patients meeting selection criteria aged between 18 and 65 years who visited participating community pharmacies to check any of five pre-MetS diagnostic factors were included.The study involved 23 community pharmacies in Catalonia (Spain). Detection criteria for pre-MetS were based on the WHO proposal following IDF and AHA/NHBI consensus. Cardiovascular risk (CVR) was calculated by Regicor and Score methods. Other variables studied were smoking habit, physical activity, body mass index (BMI), and pharmacological treatment of dyslipidemia and hypertension. The data were collected and analysed with the SPSS programme. Comparisons of variables were carried out using the Student's T-test, Chi-Squared test or ANOVA test. Level of significance was 5% (0.05). RESULTS: The overall prevalence of pre-MetS was 21.9% [95% CI 18.7-25.2]. It was more prevalent in men, 25.5% [95% CI 22.1-28.9], than in women, 18.6% [95% CI 15.5-21.7], and distribution increased with age. The most common risk factors were high blood pressure and abdominal obesity. About 70% of people with pre-MetS were sedentary and over 85% had a BMI ≥25 Kg/m2. Some 22.4% had two metabolic criteria and 27.2% of patients with pre-MetS had no previous diagnosis. CONCLUSIONS: The prevalence of pre-MetS in our study (21.9%) was similar to that found in other studies carried out in Primary Care in Spain. The results of this study confirm emergent cardiometabolic risk factors such as hypertension, obesity and physical inactivity.Our study highlights the strategic role of the community pharmacy in the detection of pre-MetS in the apparently healthy population.

Cost-effectiveness of a community pharmacist intervention in patients with depression: a randomized controlled trial (PRODEFAR Study).

BACKGROUND: Non-adherence to antidepressants generates higher costs for the treatment of depression. Little is known about the cost-effectiveness of pharmacist's interventions aimed at improving adherence to antidepressants. The study aimed to evaluate the cost-effectiveness of a community pharmacist intervention in comparison with usual care in depressed patients initiating treatment with antidepressants in primary care. METHODS: Patients were recruited by general practitioners and randomized to community pharmacist intervention (87) that received an educational intervention and usual care (92). Adherence to antidepressants, clinical symptoms, Quality-Adjusted Life-Years (QALYs), use of healthcare services and productivity losses were measured at baseline, 3 and 6 months. RESULTS: There were no significant differences between groups in costs or effects. From a societal perspective, the incremental cost-effectiveness ratio (ICER) for the community pharmacist intervention compared with usual care was €1,866 for extra adherent patient and €9,872 per extra QALY. In terms of remission of depressive symptoms, the usual care dominated the community pharmacist intervention. If willingness to pay (WTP) is €30,000 per extra adherent patient, remission of symptoms or QALYs, the probability of the community pharmacist intervention being cost-effective was 0.71, 0.46 and 0.75, respectively (societal perspective). From a healthcare perspective, the probability of the community pharmacist intervention being cost-effective in terms of adherence, QALYs and remission was of 0.71, 0.76 and 0.46, respectively, if WTP is €30,000. CONCLUSION: A brief community pharmacist intervention addressed to depressed patients initiating antidepressant treatment showed a probability of being cost-effective of 0.71 and 0.75 in terms of improvement of adherence and QALYs, respectively, when compared to usual care. Regular implementation of the community pharmacist intervention is not recommended. TRIAL REGISTRATION: ClinicalTrials.gov NCT00794196.

Effectiveness of a drug dosing service provided by community pharmacists in polymedicated elderly patients with renal impairment--a comparative study.

BACKGROUND: Drug dosing errors are common in renal-impaired patients. Appropriate dosing adjustment and drug selection is important to ensure patients' safety and to avoid adverse drug effects and poor outcomes. There are few studies on this issue in community pharmacies. The aims of this study were, firstly, to determine the prevalence of dosing inadequacy as a consequence of renal impairment in patients over 65 taking 3 or more drug products who were being attended in community pharmacies and, secondly, to evaluate the effectiveness of the community pharmacist's intervention in improving dosing inadequacy in these patients when compared with usual care. METHODS: The study was carried out in 40 Spanish community pharmacies. The study had two phases: the first, with an observational, multicentre, cross sectional design, served to determine the dosing inadequacy, the drug-related problems per patient and to obtain the control group. The second phase, with a controlled study with historical control group, was the intervention phase. When dosing adjustments were needed, the pharmacists made recommendations to the physicians. A comparison was made between the control and the intervention group regarding the prevalence of drug dosing inadequacy and the mean number of drug-related problems per patient. RESULTS: The mean of the prevalence of drug dosing inadequacy was 17.5% [95% CI 14.6-21.5] in phase 1 and 15.5% [95% CI 14.5-16.6] in phase 2. The mean number of drug-related problems per patient was 0.7 [95% CI 0.5-0.8] in phase 1 and 0.50 [95% CI 0.4-0.6] in phase 2. The difference in the prevalence of dosing inadequacy between the control and intervention group before the pharmacists' intervention was 0.73% [95% CI (-6.0) - 7.5] and after the pharmacists' intervention it was 13.5% [95% CI 8.0 - 19.5] (p < 0.001) while the difference in the mean of drug-related problems per patient before the pharmacists' intervention was 0.05 [95% CI( -0.2) - 0.3] and following the intervention it was 0.5 [95% CI 0.3 - 0.7] (p < 0.001). CONCLUSION: A drug dosing adjustment service for elderly patients with renal impairment in community pharmacies can increase the proportion of adequate drug dosing, and improve the drug-related problems per patient. Collaborative practice with physicians can improve these results.

Los servicios farmacéuticos desde la perspectiva asistencial. Análisis de situación y líneas estratégicas / The pharmaceutical services from an assistance perspective. Analysis of situation and strategics lines

No disponible